Nivolumab monotherapy after induction chemotherapy， bioradiotherapy， and cetuximab monotherapy leading to complete remission of locoregional advanced tongue cancer: A case report
Nivolumab monotherapy after induction chemotherapy， bioradiotherapy， and cetuximab monotherapy leading to complete remission of locoregional advanced tongue cancer: A case report
复制标题
诱导化疗、生物放射治疗和西妥昔单抗单药治疗后的纳武单抗单药治疗导致局部晚期舌癌完全缓解：病例报告
DOI：
10.1002/osi2.1114
复制
发表时间：
2022
影响因子：
0.5
通讯作者：
Yoshioka Y， Hamana T， Mishima T， Tani R， Toratani S， Okamoto T.
中科院分区：
文献类型：
--
作者：
K Maekawa;T Ikeuchi;S Shinkai;H Hirano;M Fujisawa;et al.;坂本和基，大野 彩，三野卓哉，黒﨑陽子，下村侑司，大森 江，樋口隆晴，小山絵理，徳本佳奈，縄稚久美子，窪木拓男;Ito N， Tani R， Obayashi F， Okamoto K， Toratani S， Okamoto T.;Yoshioka Y， Hamana T， Mishima T， Tani R， Toratani S， Okamoto T.
在此，我们报告一位66岁的女性局部晚期舌癌。她被诊断为左侧舌癌，并在多西他赛、顺铂和5-氟尿嘧啶诱导化疗（IC）后使用纳武单抗单药治疗实现完全缓解，随后进行调强生物放射治疗和西妥昔单抗单药治疗。生物放射治疗后，她接受了70个周期的西妥昔单抗单药治疗。IC和生物放射治疗均具有抗肿瘤作用。然而，原发性肿瘤复发发生。她接受了nivolumab治疗，18个周期后复发性病变消失。她已经活了5年多，在此期间成功地控制了晚期舌癌的局部控制。
Herein, we report on a 66‐year‐old woman with locoregional advanced tongue cancer. She was diagnosed with left side tongue carcinoma and achieved complete remission using nivolumab monotherapy after induction chemotherapy (IC) with docetaxel, cisplatin, and 5‐fluorouracil, followed by intensity‐modulated bioradiotherapy and cetuximab monotherapy. Following bioradiotherapy, she was administered 70 cycles of cetuximab monotherapy. Both IC and bioradiotherapy exerted antitumor effects. However, primary tumor recurrence occurred. She received nivolumab, and the recurrent lesion disappeared after 18 cycles. She has been alive and well for >5 years, showing a successful locoregional control for advanced tongue cancer during this period.